|
Market Closed -
Nasdaq
23:00:00 14/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 8.050 USD | -0.25% |
|
-4.17% | +3.21% |
| 10-05 | Biocryst Pharmaceuticals, Inc. Announces Formation of Scientific Advisory Board | CI |
| 10-05 | BioCryst Pharmaceuticals Forms Scientific Advisory Board as R&D Model Evolves | MT |
Company Valuation: BioCryst Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,492 | 2,140 | 1,227 | 1,558 | 1,642 | 2,057 | - | - |
| Change | - | -14.12% | -42.68% | 26.97% | 5.43% | 25.26% | - | - |
| Enterprise Value (EV) 1 | 2,124 | 2,140 | 1,654 | 2,065 | 1,642 | 2,175 | 1,949 | 1,639 |
| Change | - | 0.77% | -22.74% | 24.91% | -20.49% | 32.44% | -10.41% | -15.89% |
| P/E | -13.4x | -8.63x | -5.08x | -17.5x | 6.45x | -3.49x | 12.1x | 10.6x |
| PBR | -23.9x | -7.32x | -2.71x | -3.27x | - | -7.24x | 30,962x | 5.66x |
| PEG | - | -0.3x | 0.5x | 0.3x | -0x | 0x | -0x | 0.7x |
| Capitalization / Revenue | 15.9x | 7.9x | 3.7x | 3.46x | 1.88x | 2.9x | 2.78x | 2.47x |
| EV / Revenue | 13.5x | 7.9x | 4.99x | 4.58x | 1.88x | 3.06x | 2.64x | 1.97x |
| EV / EBITDA | -12x | -14.6x | -16.2x | -1,592x | 4.8x | -12.5x | 9.96x | 5.82x |
| EV / EBIT | -12x | -14.4x | -15.9x | -812x | 4.82x | -4.28x | 7.88x | 5.19x |
| EV / FCF | -14.7x | -13.1x | -17x | -38.9x | 4.76x | -96.6x | 7.37x | 4.12x |
| FCF Yield | -6.81% | -7.63% | -5.88% | -2.57% | 21% | -1.04% | 13.6% | 24.3% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.03 | -1.33 | -1.18 | -0.43 | 1.21 | -2.31 | 0.6635 | 0.7615 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 157.2 | 270.8 | 331.4 | 450.7 | 874.8 | 710.1 | 738.7 | 834 |
| EBITDA 1 | -176.9 | -147 | -102.1 | -1.297 | 342.4 | -173.5 | 195.7 | 281.8 |
| EBIT 1 | -177.7 | -148.4 | -103.7 | -2.543 | 341 | -508.2 | 247.2 | 315.5 |
| Net income 1 | -184.1 | -247.1 | -226.5 | -88.88 | 263.9 | -582.2 | 181.3 | 248.2 |
| Net Debt 1 | -368.3 | - | 426.7 | 507.7 | - | 117.9 | -108.5 | -418.2 |
| Reference price 2 | 13.850 | 11.480 | 5.990 | 7.520 | 7.800 | 8.050 | 8.050 | 8.050 |
| Nbr of stocks (in thousands) | 179,936 | 186,424 | 204,809 | 207,133 | 210,543 | 255,535 | - | - |
| Announcement Date | 2/23/22 A | 2/21/23 A | 2/26/24 A | 2/24/25 A | 2/26/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.49x | 3.07x | -12.56x | -.--% | 2.06B | |
| 20.44x | 7.28x | 14.62x | 1.45% | 70.44B | |
| 27.08x | 7.4x | 23.22x | 0.05% | 50.31B | |
| 33.03x | 5.94x | 17.79x | 0.98% | 47.51B | |
| 33.58x | 3.26x | 14.07x | -.--% | 42.91B | |
| -19.54x | 197.56x | -20.76x | -.--% | 40.39B | |
| 46.24x | 5.25x | 28.83x | -.--% | 39.69B | |
| 26.84x | 7.63x | 19.74x | 0.4% | 30.59B | |
| 30.94x | 6.59x | 17.1x | -.--% | 26.8B | |
| -13.49x | 4.97x | -6x | -.--% | 22.36B | |
| Average | 18.16x | 24.89x | 9.60x | 0.29% | 37.31B | |
| Weighted average by Cap. | 21.98x | 26.86x | 13.01x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BCRX Stock
- Valuation BioCryst Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
